Feeds:
Posts
Comments

Posts Tagged ‘Jonathan Matsey’

Zero Stage Capital Dissolves Amid Losses

Posted in Board Of Intellectual Capital, Distressed Intellectual Property, Economy, Gerbsman Partners, Intellectual capital, Investments, Venture Capital, tagged , , , , , , , , , , , , on March 5, 2009| Leave a Comment »

This current economic crisis has started to hit VC´s as well, Zero Stage Capital dissolves.

“Zero Stage Capital, a life science and IT venture firm, dissolved last year after several poorly performing funds, according to limited partners. The firm’s few remaining portfolio companies have been transferred to a newly created firm, Vox Equity Partners, managed by the son of Zero Stage’s managing director.

Originally based in Cambridge, Mass., small business investment company Zero Stage raised a $150 million sixth fund in 1999 and a roughly $160 million seventh fund in 2001. In April 2005, the firm told VentureWire it had scrapped plans for a larger, $250 million eighth fund after several personnel changes, scaling back plans to raise a $150 million vehicle for buying struggling venture-backed businesses.

Yet by 2008, according to one limited partner who wished to remain anonymous for this story, the firm was run out of Managing Director Paul Kelley’s Sommerville, Mass., home as he worked to wind down its operations.”

Read the full VentureWire article by Jonathan Matsey here.

Read Full Post »

Fixing Israel’s Life Sciences Industry

Posted in Board Of Intellectual Capital, boic, Gerbsman Partners, Investments, Venture Capital, tagged , , , , , , , , , , , , , , , , , on March 2, 2009| 1 Comment »

Here is a good article from WSJ online by Jonathan Matsey.

The Israeli life science industry was in the spotlight recently, when Medtronic Inc. agreed to pay $325 million up-front for Netanya-based Ventor Technologies Ltd., which had raised $17 million in venture financing in part from Pitango Venture Capital. While the deal was great for Ventor’s investors, Rafi Hofstein, chairman of Hadasit Bio-Holdings Ltd., a publicly traded tech-transfer company for Jerusalem’s Hadassah University Hospital, said it highlights a problem with the country’s life science industry: the inability to develop home-grown companies to fruition. And despite the global economic downturn and the re-location of many of the country’s drug and device companies overseas, Hofstein said government policy – and a possible $240 million public-sponsored biotech fund – may ultimately reignite Israel’s life science industry.

Read the full article here

Read Full Post »